Congress | hivhub.be

Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination for the treatment of people living with HIV in Argentina: first interim report of the BICTARG cohort
Cecchini et al.

This content is only accessible to healthcare professionals in Belgium. To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

Efficacy and Safety of Switching Older Adults (≥60 Years) from First-Line ART to B/F/TAF in Kenya
A Randomized Clinical Trial (the B/F/TAF Elderly Study)
Ombajo et al.

This content is only accessible to healthcare professionals in Belgium. To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

Week-96 Results of ALLIANCE, a Phase 3, Randomized, Double-Blind Study Comparing B/F/TAF Versus DTG + F/TDF in Treatment-Naïve People With Both HIV-1 and Hepatitis B

This content is only accessible to healthcare professionals in Belgium. To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

Weight Change and Metabolic Assessment of Virologically Suppressed Children With HIV Aged≥ 2 Years and Weighing 14 to < 25 Kg Who Received a TAF-Containing Regimen

This content is only accessible to healthcare professionals in Belgium. To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

Pharmacokinetics (PK), Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)in Virologically Suppressed Pregnant Women With HIV

This content is only accessible to healthcare professionals in Belgium. To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

IAS 2023

This content is only accessible to healthcare professionals in Belgium. To view our restricted content please register HERE. You will be granted immediate access. If you are already registered, please sign-in HERE. To register as a Gilead employee,...

Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination for the treatment of people living with HIV in Argentina: first interim report of the BICTARG cohortCecchini et al.

Efficacy and Safety of Switching Older Adults (≥60 Years) from First-Line ART to B/F/TAF in KenyaA Randomized Clinical Trial (the B/F/TAF Elderly Study)Ombajo et al.

Week-96 Results of ALLIANCE, a Phase 3, Randomized, Double-Blind Study Comparing B/F/TAF Versus DTG + F/TDF in Treatment-Naïve People With Both HIV-1 and Hepatitis B

Weight Change and Metabolic Assessment of Virologically Suppressed Children With HIV Aged≥ 2 Years and Weighing 14 to < 25 Kg Who Received a TAF-Containing Regimen

Pharmacokinetics (PK), Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)in Virologically Suppressed Pregnant Women With HIV

IAS 2023

Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination for the treatment of people living with HIV in Argentina: first interim report of the BICTARG cohort
Cecchini et al.

Efficacy and Safety of Switching Older Adults (≥60 Years) from First-Line ART to B/F/TAF in Kenya
A Randomized Clinical Trial (the B/F/TAF Elderly Study)
Ombajo et al.